Showing results (1951-1960 of 7,279) with videos related to

Sort By:
Pageof 728
The Japanese Journal of Veterinary Research|April 1, 1989
Use of biotinylated antibody for the assay of Hanganutziu-Deicher antibodies and antigens in fluids and tissues from cancer patientsJ K Gathuru, H Higashi, S Kato, et al.
Seishin Shinkeigaku Zasshi = Psychiatria Et Neurologia Japonica|February 5, 2004
[Efficacy of intervention with externalization therapy for eating disorders]Haruhisa Ono, Kazushige Kojima, Yutaka Higashi, et al.
Ecology and Evolution|July 28, 2012
Fine scale relationships between sex, life history, and dispersal of masu salmonShigeru Kitanishi, Toshiaki Yamamoto, Itsuro Koizumi, et al.
Rheumatology (Oxford, England)|August 11, 2012
Effectiveness of etanercept vs cyclophosphamide as treatment for patients with amyloid A amyloidosis secondary to rheumatoid arthritisTadashi Nakamura, Syu-Ichi Higashi, Kunihiko Tomoda, et al.
Quintessence International (Berlin, Germany : 1985)|May 4, 2004
Histologic evaluation of adhesive restorations on dentin caries in rat molar teethYasushi Shimada, Masatugu Kawashima, Takashi Higashi, et al.
Hinyokika Kiyo. Acta Urologica Japonica|June 4, 2008
[Primary malignant melanoma of the male urethra: a case report]Masaharu Inoue, Jun-Ichiro Ishioka, Yukio Kageyama, et al.
Cells|October 25, 2024
EF24, a Curcumin Analog, Reverses Interleukin-18-Induced miR-30a or miR-342-Dependent TRAF3IP2 Expression, RECK Suppression, and the Proinflammatory Phenotype of Human Aortic Smooth Muscle CellsYusuke Higashi, Ryan Dashek, Patrice Delafontaine, et al.
Frontiers in Oral Health|June 26, 2024
An inflammatory paradox: strategies inflammophilic oral pathobionts employ to exploit innate immunity via neutrophil manipulationDustin L Higashi, Hua Qin, Christina Borland, et al.
EMBO Reports|March 24, 2007
Simultaneous induction of the four subunits of the TRAP complex by ER stress accelerates ER degradationKoji Nagasawa, Toshio Higashi, Nobuko Hosokawa, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|May 22, 2007
Incorporation of TIP (paclitaxel, ifosfamide, cisplatin) into first-line therapy for intermediate to poor risk testicular germ cell tumors with unfavorable marker decline after initial two cycles chemotherapy: a report of three casesJun-Ichiro Ishioka, Yukio Kageyama, Nobutaka Ichiyanagi, et al.
Pageof 728